key: cord-0994558-kfjm95p9 authors: Murray, Matthew J.; Moleron, Rafael; Adamski, Jennifer; English, Martin; Burke, G. A. Amos; Cross, Justin; Ajithkumar, Thankamma; Stoneham, Sara; Nicholson, James C. title: Vinblastine monotherapy induction prior to radiotherapy for patients with intracranial germinoma during the COVID‐19 pandemic date: 2021-09-14 journal: Pediatr Blood Cancer DOI: 10.1002/pbc.29359 sha: 74ed1d84f4c019903c20f0207279726a53f7fd41 doc_id: 994558 cord_uid: kfjm95p9 BACKGROUND: Patients with localized intracranial germinoma have excellent survival. Reducing treatment burden and long‐term sequelae is a priority. Intensive inpatient chemotherapy (e.g., carboPEI = carboplatin/etoposide/ifosfamide) has been effectively employed to reduce radiotherapy treatment volume/dose. Outpatient‐based carboplatin monotherapy is associated with excellent outcomes in metastatic testicular seminoma (an identical pathology), and successful vinblastine monotherapy induction (with 77% tumor volume reduction after just two weekly vinblastine doses) has recently been reported in an intracranial germinoma patient. METHODS: Adapted UK guidelines for germ cell tumor management were distributed during the COVID‐19 pandemic, including nonstandard treatment options to reduce hospital visits and/or admissions. This included vinblastine monotherapy for intracranial germinoma (6 mg/m(2) intravenously, or 4 mg/m(2) for moderate count suppression, delivered weekly). We describe two such patients treated using this approach. RESULTS: A 30‐year‐old male with a localized pineal tumor received 12‐week vinblastine induction, with >60% volume reduction, prior to definitive radiotherapy. A 12‐year‐old female with a metastatic suprasellar tumor and progression at all sites of disease whilst awaiting proton radiotherapy received two vinblastine doses with good early response, including 36% primary tumor volume reduction. The patients tolerated vinblastine well. CONCLUSION: Patients with intracranial germinoma have excellent outcomes, and reduction of late effects remains a priority. The description of vinblastine monotherapy in these intracranial germinoma patients warrants further exploration. Intracranial germ cell tumors (GCTs) are rare, and diagnosis and management are challenging due to their heterogeneity, for example, regarding differing tumor sites, histological subtypes, and marker expression. For germinoma patients, which comprise the majority of intracranial GCT cases, 1 the internationally agreed priority for future management is to maintain excellent overall survival whilst attempting to reduce treatment burden and minimize late effects and sequelae of treatment. 2 Historically, craniospinal irradiation (CSI) was used to treat all intracranial germinoma patients, regardless of metastatic status, 3, 4 although the requirement for CSI in localized disease was questioned. 5 A chemotherapy-only approach for cure has also been attempted but was unsuccessful, 6 and thus radiotherapy remains the definitive treatment. However, use of intensive inpatient induction chemotherapy, prior to radiotherapy, for localized intracranial germinoma patients has been effective in reducing radiotherapy treatment volume and/or dose whilst maintaining survival. [7] [8] [9] In Europe, "carboPEI" (alternating courses of carboplatin/etoposide and ifosfamide/etoposide) has been used for this purpose. 7, 8 CarboPEI involves prolonged inpatient stays and use of intravenous hydration. Given the common comorbidity of central diabetes insipidus (DI) in patients with neurohypophyseal-suprasellar germinoma, use of a chemotherapy regimen without concomitant intravenous hydration would be a major advantage. 10 Of note, in a study of 32 patients with intracranial GCT receiving cisplatin-and/or ifosfamide-based chemotherapy, 21 (66%) had DI and, furthermore, six of these 21 patients (29%) experienced serious complications. 10 In addition to the challenges of managing DI, carboPEI chemotherapy is associated with short-term toxicities of myelosuppression, vomiting and/or diarrhoea, electrolyte disturbances, which may lead to seizures, renal impairment and elevation of liver enzymes. 8 Long-term sequelae of these drugs include ototoxicity from cisplatin 11 and reduced fertility from alkylating agents (ifosfamide). 12, 13 Current chemotherapy regimens also require the use of indwelling central venous access devices, which are associated with increased risk of infection 14 and thrombosis 15 and which may affect quality of life. In North America, the standard-of-care schedule to reduce radiotherapy treatment volume and/or dose is carboplatin-etoposide. 9 Similar to carboPEI, there is an associated, albeit small, second malignancy risk with etoposide. 16 Of note, outpatient-based single-agent carboplatin chemotherapy is associated with excellent outcomes in metastatic testicular seminoma, 17, 18 an identical pathology to intracranial germinoma (and ovarian dysgerminoma). Carboplatin monotherapy, at modest dosing, has also been successfully utilized in intracranial germinoma to allow a reduction in subsequent radiotherapy doses. 19 Furthermore, we recently reported successful vinblastine monotherapy induction, prior to radiotherapy, in a patient with intracranial germinoma. 20 The patient presented with complete loss of vision, and imaging demonstrated a suprasellar lesion, measuring 36 × 28 × 23 mm. The initial working diagnosis was low-grade glioma and accordingly, weekly vinblastine monotherapy was commenced. Vision returned within 4 days of starting vinblastine and after further review, the diagnosis was revised to germinoma. After dramatic radiological reduction in tumor size after just two vinblastine doses (to 21 × 19 × 12 mm; a 77% volume reduction), a 12-week induction course was delivered, with excellent response, prior to radiotherapy. 20 Importantly, both carboplatin and vinblastine schedules can be successfully delivered peripherally without recourse to placement of a central venous access device. Due to the COVID-19 pandemic, adapted UK guidelines for GCT patient management were distributed to clinicians, including potential nonstandard treatment options that would reduce hospital visits and/or admissions. This included vinblastine monotherapy as an option for intracranial germinoma, based on our case report 20 and practical/pragmatic considerations. We describe two patients successfully treated using this approach. The experience of vinblastine monotherapy in these patients warrants further exploration. was <0.75 × 10 9 /L but ≥0.5 × 10 9 /L and/or platelet count <75 × 10 9 /L but ≥50 × 10 9 /L, the dose was reduced to 66% (4 mg/m 2 ). Finally, if the neutrophil count was <0.5 × 10 9 /L and/or platelet count <50 × 10 9 /L, vinblastine was held until count recovery. Adequate renal and liver function was checked by monthly blood testing. Appropriate consent for nonstandard treatment was obtained. Due to the older age of the patient (30 years) and anticipated reduction in tolerance, vinblastine was commenced at 4 mg/m 2 dosing. This was well tolerated and therefore the dose for week 2 was increased to the standard 6 mg/m 2 dose. 21, 22 However, this resulted in neutropenia Figure 1D ). T2/FLAIR sequences ( Figure S1 ) did not provide additional information to that obtained with T1 sequences with contrast. felt that intervention with chemotherapy treatment prior to CSI was required. The patient did not have central access and due to concerns that myelosuppression from carboPEI chemotherapy may delay radiation planning and delivery, vinblastine was suggested based on our earlier report. 20 The case was discussed at the CCLG GCTNAP and it was agreed that it was reasonable to proceed with weekly vinblastine whilst awaiting the start of proton radiotherapy. Accordingly, two doses at 6 mg/m 2 were delivered peripherally, well toler- Figure 2D ). T2/FLAIR sequences ( Figure S2 ) did not provide additional information to that obtained with T1 sequences with contrast. Patients with intracranial germinoma have excellent outcomes, but reducing treatment effects remains a priority. 2 In Europe, carboPEI 7 is delivered with large volumes of intravenous hydration, can exacerbate pre-existing DI, particularly where no thirst mechanism is present, and is associated with prolonged inpatient admissions. 20 Such chemotherapy schedules are also associated with short-8 and longterm [11] [12] [13] 16 toxicities and, moreover, require central venous access devices for delivery, with associated infection and thrombosis risk. 14, 15 A further UK intracranial germinoma case, in addition to the two formally described here, received two vinblastine doses to complete induction as a "bridge" to radiotherapy with stable radiological appear- there is interest in using gentle "window" chemotherapy to bridge individuals to radiotherapy. If successful, this may also facilitate a reduction in radiotherapy treatment volume for macroscopic disease at diagnosis. The malignant GCT subtype germinoma and its extracranial testicular counterpart seminoma are indistinguishable pathologically, with biological evidence suggesting that these tumors share a common molecular pathogenesis. 24 Germinoma/seminoma are known to be exquisitely chemosensitive, in addition to their radiosensitivity. Carboplatin monotherapy has been successfully employed for metastatic testicular seminoma with excellent outcomes 17, 18 and at modest dosing has been utilized in intracranial germinoma permitting radiotherapy dose reductions. 19 Vinblastine has also been used within multiagent regimens to treat intracranial germinoma, 25 and the induction response to vinblastine monotherapy 20 is noteworthy. Weekly vinblastine monotherapy is well tolerated with minimal side effects for treatment of other central nervous system conditions such as low-grade glioma and Langerhans cell histiocytosis. 21, 22, 26 It can also be delivered peripherally as an intravenous bolus in an outpatient setting in some treatment centers. 20 Further potential advantages of monotherapy induction for intracranial germinoma include patient and carer benefit, consistent with recent patient and public involvement (PPI) work 27 and benefit for lower-and middle-income countries (Supporting Information: Discussion). Our case series has a number of limitations. The numbers of patients described is very small and only one of the two patients received a "full" induction course. However, the cases described here during the COVID-19 pandemic, along with a previously described case, 20 suggest that further investigation is warranted to assess the role for induction monotherapy, prior to definitive radiotherapy, more formally in the context of a clinical trial. This should include study of complete remission rates after induction, as in future this may allow omission of radiotherapy boosts. In addition, it should be noted that any potential reduction in therapy for cancer could be associated with a theoretical increase in relapse risk. Consequently, prior to implementation, it is important to understand how effective any treatment for potential relapse is. Due to the effectiveness of existing therapies, relapsed intracranial germinoma is rare and data are relatively sparse. However, evidence to date shows that patients with relapsed germinoma can be successfully cured, even following the intensity of current first-line therapy. [28] [29] [30] In summary, patients with intracranial germinoma have excellent outcomes and reduction of treatment effects remains a priority. The chemosensitivity of germinoma and description of vinblastine monotherapy in these two cases, along with our previous report, 20 warrant further exploration. Germ cell tumours in children and adolescents. Paediatr Child Health Consensus on the management of intracranial germ-cell tumours Midline pineal tumors and suprasellar germinomas: highly curable by irradiation Treatment results of intracranial germinoma as a function of the irradiated volume Radiotherapy of primary intracranial germinomas: the case against routine craniospinal irradiation Intensive cisplatin and cyclophosphamide-based chemotherapy without radiotherapy for intracranial germinomas: failure of a primary chemotherapy approach Combined treatment modality for intracranial germinomas: results of a multicentre SFOP experience Societe Francaise d'Oncologie Pediatrique SIOP CNS GCT 96: final report of outcome of a prospective, multinational nonrandomized trial for children and adults with intracranial germinoma, comparing craniospinal irradiation alone with chemotherapy followed by focal primary site irradiation for patients with localized disease Treatment of primary CNS germinomatous germ cell tumors with chemotherapy prior to reduced dose whole ventricular and local boost irradiation. Pediatr Blood Cancer Challenges in management of patients with intracranial germ cell tumor and diabetes insipidus treated with cisplatin and/or ifosfamide based chemotherapy Long-term toxicity of intracranial germ cell tumor treatment in adolescents and young adults Does ifosfamide affect gonadal function? Does ifosfamide affect gonadal function? Pediatr Blood Cancer Histologic analysis of testes from prepubertal patients treated with chemotherapy associates impaired germ cell counts with cumulative doses of cyclophosphamide, ifosfamide, cytarabine, and asparaginase Incidence, severity and outcome of central line related complications in pediatric oncology patients; a single-center study Risk factors for central venous access devicerelated thrombosis in hospitalized children: a systematic review and meta-analysis Second malignant neoplasms and cause of death in patients with germ cell cancer: a Danish nationwide cohort study Carboplatin AUC 10 for IGCCCG good prognosis metastatic seminoma Single-agent carboplatin AUC10 in metastatic seminoma: a multi-centre UK study of 216 patients A phase II trial of preirradiation carboplatin in newly diagnosed germinoma of the central nervous system Clinical utility of circulating miR-371a-3p for the management of patients with intracranial malignant germ cell tumors Weekly vinblastine in pediatric low-grade glioma patients with carboplatin allergic reaction. Cancer Phase II weekly vinblastine for chemotherapy-naive children with progressive low-grade glioma: a Canadian pediatric brain tumor consortium study Ifosfamide-related encephalopathy with severe clinical presentations in children with cancer Recurrent neomorphic mutations of MTOR in central nervous system and testicular germ cell tumors may be targeted for therapy Cisplatin, vinblastine and bleomycin (PVB) combination chemotherapy in the treatment of intracranial malignant germ cell tumors-a preliminary report of a phase II study-the Japanese Intracranial Germ Cell Tumor Study Group Efficacy of vinblastine in central nervous system Langerhans cell histiocytosis: a nationwide retrospective study The UK top research priorities for living with and beyond cancer. NCRI. 2019. Accessed Thiotepa-based high-dose chemotherapy with autologous stem-cell rescue in patients with recurrent or progressive CNS germ cell tumors Treatment and outcomes of UK and German patients with relapsed intracranial germ cell tumors following uniform first-line therapy Relapsing intracranial germ cell tumours warrant retreatment We thank the patients, their families, and the clinical teams who, after discussion, consented to nonstandard treatment with vinblastine as part of the management of intracranial germinoma during the COVID-19 pandemic and consented to publication. We thank Dr Richard Gagan, Neuroradiology Department, Birmingham Children's Hospital for assistance in provision of the representative images for Case 2. The authors declare that there is no conflict of interest. The data that support the findings of this study are available from the corresponding author upon reasonable request. Matthew J. Murray https://orcid.org/0000-0002-4480-1147 Sara Stoneham https://orcid.org/0000-0001-5482-648X Additional supporting information may be found in the online version of the article at the publisher's website.